Meng XD 2003.

Methods	Country: China Setting: hospital based Aim: to study the effects of Gujian capsule in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T‐test, Chi2 test Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 68 primary osteoporosis patients enrolled: 35 in trial group (1 drop‐out), 33 in control group (2 drop‐out) Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.
Interventions	Experimental: Gujian capsule (2 capsules, 3 times a day), for 6 months Control: alfacalcidol (0.5 μg, twice a day), for 6 months
Outcomes	BMD, PTH, CT, E2, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias